AJR F and L Medical Products: Radiation Protection & More
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, S. H.
Right arrow Articles by Choi, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, S. H.
Right arrow Articles by Choi, B. I.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.07.2565
AJR 2008; 191:529-536
© American Roentgen Ray Society


Original Research

Hepatocellular Carcinoma in Liver Transplantation Candidates: Detection with Gadobenate Dimeglumine–Enhanced MRI

Seung Hong Choi1, Jeong Min Lee1, Nam C. Yu2, Kyung-Suk Suh3, Ja-June Jang4, Se Hyung Kim1 and Byung Ihn Choi1

1 Department of Radiology and Institute of Radiation Medicine, Seoul National University College of Medicine, Clinical Research Institute, Seoul National University Hospital, 28, Yongon-dong, Chongno-gu, Seoul, 110-744, Korea.
2 Department of Radiology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA.
3 Department of Surgery, Seoul National University Hospital, Seoul, Korea.
4 Department of Pathology, Seoul National University Hospital, Seoul, Korea.

OBJECTIVE. The purpose of this study was to retrospectively evaluate the diagnostic performance of dynamic gadobenate dimeglumine–enhanced MRI with explant pathologic correlation in the detection of hepatocellular carcinoma (HCC) in patients undergoing liver transplantation.

MATERIALS AND METHODS. Forty-seven patients (28 men, 19 women; mean age, 49 years) underwent dynamic gadobenate dimeglumine–enhanced MRI within 3 months before primary liver transplantation. Dynamic imaging was performed before (unenhanced) and after (hepatic arterial, portal venous, equilibrium, and 1-hour delayed phases) IV bolus administration of gadobenate dimeglumine at 0.1 mmol/kg body weight. Retrospective image analysis to detect HCC nodules was performed independently by two abdominal radiologists who had no pathologic information. On a per-nodule basis, the sensitivity and positive predictive value were calculated for the two observers. Sensitivity and specificity in the diagnosis of HCC also were evaluated. Fisher's exact test was performed to determine whether there was a detection difference between HCC nodules 1 cm in diameter or larger and nodules smaller than 1 cm and to evaluate the differences in causes of false-positive MRI findings based on lesion size (≥ 1 cm vs < 1 cm).

RESULTS. Twenty-seven patients had 41 HCCs. In HCC detection, gadobenate dimeglumine–enhanced MRI had a sensitivity of 85% (35 of 41 HCCs) and a positive predictive value of 66% (35 of 53 readings) for observer 1 and a sensitivity of 80% (33 of 41 HCCs) and a positive predictive value of 65% (34 of 52 readings) for observer 2. For both observers, sensitivity in the detection of HCCs 1 cm in diameter and larger (91–94%) was significantly different (p < 0.05) from that in detection of HCCs smaller than 1 cm (29–43%). Nonneoplastic arterial hypervascular lesions more often caused false-positive diagnoses of lesions smaller than 1 cm in diameter (80–86%) on MR images than of those 1 cm in diameter and larger (0–25%). The difference was statistically significant (p < 0.05) for both observers. In diagnosis, gadobenate dimeglumine–enhanced MRI had a sensitivity of 87% (20 of 23 patients) and a specificity of 79% (19 of 24 patients) for both observers.

CONCLUSION. Dynamic gadobenate dimeglumine–enhanced MRI has a sensitivity of 80–85% and a positive predictive value of 65–66% in the detection of HCC. The technique, however, is of limited value for detecting and characterizing lesions smaller than 1 cm in diameter.

Keywords: gadobenate dimeglumine • hepatocellular carcinoma • liver cirrhosis • MRI


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
RadioGraphicsHome page
S. M. Hussain, C. Reinhold, and D. G. Mitchell
Cirrhosis and Lesion Characterization at MR Imaging.
RadioGraphics, October 1, 2009; 29(6): 1637 - 1652.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
M. K. Seale, O. A. Catalano, S. Saini, P. F. Hahn, and D. V. Sahani
Hepatobiliary-specific MR Contrast Agents: Role in Imaging the Liver and Biliary Tree.
RadioGraphics, October 1, 2009; 29(6): 1725 - 1748.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Roentgen Ray Society.